BIO 2026: Biopharma dealmakers seek to protect ‘premium pricing’ from Trump’s MFN policy

With drug pricing now embedded in U.S. policy, business development teams in biotech and pharma are changing the way they strike deals, including acknowledging policy uncertainties with renegotiation clauses.